News | Blood Testing | January 12, 2016

Emerging Biomarkers Disrupt Cardiac Diagnostics

The rise of a value-based healthcare system in the U.S. has opened more opportunities for the cardiac biomarker diagnostic industry, finds Frost & Sullivan

Frost & Sullivan, biomarkers, cardiac disease diagnosis, analysis

January 12, 2016 — Even though brain natriuretic peptide (BNP)/pro-BNP and troponin biomarkers are the gold standard for cardiac disease diagnosis, end users will soon see additional alternative biomarkers entering the market, according to analysis from Frost & Sullivan. By 2024, emerging biomarkers such as ST2 Galectin-3 are becoming more sensitive in diagnosing cardiovascular disease and will penetrate the lab-based and point-of-care (POC) end user segments.

The report, Analysis of the Cardiac Biomarker Diagnostics Market, finds the market earned revenues of $551 million in 2014 and estimates this to reach $813.8 million in 2021 at a compound annual growth rate of 5.7 percent.

The biggest opportunity for cardiac biomarker diagnostic manufacturers lies in providing a wholesome platform allowing for quick yet well-rounded diagnoses of patients. Companies such as Siemens are at an advantage in terms of product development, as they are leaders in both clinical diagnosis and diagnostic imaging.

“Obtaining an accurate and early diagnosis is no longer as challenging with the increased use of advanced POC tests (POCTs),” said Frost & Sullivan Transformational Health Industry Analyst Aish Vivekanandan. “The higher adoption of POCTs in clinical and ambulatory settings has given a significant boost to the cardiac biomarker diagnostics market.”

An additional impetus has been the implementation of the U.S. Affordable Care Act (ACA), designed to improve healthcare accessibility. The ACA initiated a shift towards value-based care, which has increased the pressure on hospitals to invest in more efficient and accurate products.

“POCT is growing at a faster rate than lab-based tests and will spur the growth in this market, however lab-based tests remain the “gold” standard,” observed Vivekanandan. “The growing budget constraints and the push for value-based healthcare opens opportunities for the POCT market as it offers a quick turn-around-time, providing early diagnosis which is crucial for surviving heart diseases.”

There is tremendous opportunity for cardiac biomarker diagnostics to be used as a companion diagnostic tool to monitor patients undergoing drug treatment. Additionally, they could integrate digital apps enabling access to consumer behavior analytics, as well as offer consultations and services for biomarker testing for long-term success.

For more information: www.frost.com

Related Content

Abbott Point-of-Care Blood Test Speeds Heart Attack Diagnosis
News | Blood Testing | October 26, 2018
For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether...
New Noninvasive Blood Glucose Test as Effective as Finger Prick

Image courtesy of University of Missouri School of Medicine

News | Blood Testing | October 24, 2018
For those living with diabetes, monitoring blood glucose accurately is necessary to prevent diabetes-related...
Abbott Receives CE Mark for High Sensitive Troponin-I Test
News | Blood Testing | October 16, 2018
October 16, 2018 — Abbott announced that its High Sensitive Troponin-I...
AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patient
News | Blood Testing | September 04, 2018
Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD)...
More Sensitive Blood Test Diagnoses Heart Attacks Faster
News | Blood Testing | August 06, 2018
August 6, 2018 — A new test to assess a whether or not someone is having a...
Singulex cTnl Assay Can Identify Presence, Severity of CAD in Stable, Symptomatic Outpatients
News | Blood Testing | March 26, 2018
March 26, 2018 — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singule
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
Overlay Init